Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-090-3 | CAS number: 51-34-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The most sensitive subchronic value of 45 mg/kg bw (five days a week) was determined in a NTP (National Toxicology Program) study conducted with rats in the 14 -weeks study (oral gavage). The exposure for five days per week under test conditions was extrapolated to seven days per week resulting in the NOAEL value of 32.14 mg/kg bw/day.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study
- Justification for type of information:
- The read-across justification is included as attachmant to Iuclid section 13.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Deviations:
- yes
- Remarks:
- Clinical biochemistry and ophthalmological examination was not conducted
- GLP compliance:
- yes
- Remarks:
- Food and Drug Administration (FDA) Good Laboratory Practice Regulations (21 CFR, Part 58)
- Limit test:
- no
- Species:
- rat
- Strain:
- other: F344/N
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Simonsen Laboratories, Inc. (Gilroy, CA)
- Age at study initiation: approximately 6 weeks
- Average age at Necropsy: approximately 19 to 20 weeks
- Weight at study initiation: mean body weight: male 114 to 116 +-3 g, female 95+-1 to 98+-2g
- Housing: 5 per cage; Cages: Polycarbonate (Lab Products Inc., Maywood, NJ), changed twice weekly; Bedding: Beta Chips® (Northeastern Products Co., Warrensburg, NY); Cage filters: Reemay® spun-bonded polyester (Andico, Birmingham, AL); Racks: Stainless steel (Lab Products Inc., Maywood, NJ), rotated once every 2 weeks
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 12 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 to 25°C- Humidity (%): 45 to 66%
- Air changes (per hr): minimum of 10 changes/hour
- Photoperiod (hrs dark / hrs light): 12 hours/day fluorescent light - Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- deionized
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Stability studies of the 11 and 0.2 mg/mL dose formulations were conducted by the analytical chemistry laboratory. For the 11 mg/mL formulation, samples were prepared by dissolving scopolamine hydrobromide trihydrate in deionized water and diluting to volume. Aliquots (5 mL) were mixed with internal standard solution (0.4 mg/mL acetophenone in acetonitrile) and were further diluted with 0.007 M aqueous sodium heptanesulfonic acid. The samples were then analyzed by HPLC using a Waters C18 Nova Pak column, with a mobile phase of water:acetonitrile (70:30), at a flow rate of 1.0 mL/minute, and with ultraviolet detection at 229 nm. For the 0.2 mg/mL formulation, samples were prepared by dissolving scopolamine hydrobromide trihydrate in deionized water and diluting to volume. Aliquots (7 mL) were mixed with internal standard solution (0.04 mg/mL propiophenone in acetonitrile) and were analyzed by HPLC with the same system used to analyze the 11 mg/mL formulation but with a mobile phase ratio of 75:25. The stability of the dose formulations was confirmed for at least 3 weeks at room temperature when stored in the dark or for at least 3 hours at room temperature and open to air and light.Periodic analyses of the dose formulations of scopolamine hydrobromide trihydrate were conducted at the study laboratory using ultraviolet/visible spectrometry for the 14-week studies. During the 14-week studies, dose formulations were analyzed every 6 to 8 weeks. All of the dose formulations analyzed during the 14-week studies were within 10% of the target concentration. For the 14-week , results of periodic referee analyses performed by the analytical chemistry laboratory indicated good agreement with the results of the study laboratory.
- Duration of treatment / exposure:
- 14 weeks
- Frequency of treatment:
- once daily, 5 days per week
- Remarks:
- Doses / Concentrations:0, 15, 45, 135, 400, or 1,200 mg/kg bw
- No. of animals per sex per dose:
- 10
- Control animals:
- yes
- Details on study design:
- - Sentinel program: The Sentinel Animal Program is part of the periodic monitoring of animal health that occurs during the toxicologic evaluation of chemical compounds. Under this program, the disease state of the rodents is monitored via serology on sera from extra (sentinel) animals in the study rooms. These animals and the study animals are all subject to identical environmental conditions. The sentinel animals come from the same production source and weanling groups as the animals used for the studies of chemical compounds.
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes - Time schedule: twice daily
DETAILED CLINICAL OBSERVATIONS: Yes - Time schedule: weekly
BODY WEIGHT: Yes - Time schedule for examinations: initially, weekly, and at the end of the study
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): feed conumption were recorded weekly by cage
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes - Time schedule for collection of blood: at the end of the study- Anaesthetic used for blood collection: Yes carbon dioxide- Parameters checked which were examined: hematocrit; hemoglobin; erythrocyte, reticulocyte, and nucleated erythrocyte counts; mean cell volume; mean cell hemoglobin; mean cell hemoglobin concentration; platelet count; and leukocyte count and differentials.
CLINICAL CHEMISTRY: No
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No
OTHER:SPERM MORPHOLOGY AND VAGINAL CYTOLOGY: Yes; From rats receiving 0, 45, 135, 400 mg/kg- The parameters evaluated in males were sperm count, morphology, and motility.The right cauda, right epididymis, and right testis were weighed. Vaginal fluid samples were collected for up to 7 consecutive days prior to the end of the studies for vaginal cytology evaluations. The parameters evaluated in females were relative frequency of estrous stages and estrous cycle length.
NECROPSY: Yes- All animals were necropsied. Organs weighed included the brain, heart, right kidney, liver, lungs, right ovary, right testis, thymus and uterus. - Sacrifice and pathology:
- HISTOPATHOLOGY/GROSS PATHOLOGY: Yes; Complete histopathologic examinations were performed on all control rats, male rats receiving 135 mg/kg or higher, female rats receiving 400 mg/kg or higher. In addition to gross lesions, tissue masses and associated lymph nodes, the tissues examined included: adrenal gland, bone and marrow, brain, clitoral gland, esophagus, heart, kidney, large intestine (cecum, colon, and rectum), small intestine (duodenum, jejunum, and ileum), liver, lung, lymph nodes (mandibular and mesenteric), mammary gland, nose, ovary, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, skin, spleen, stomach (forestomach and glandular stomach), testis with epididymis and seminal vesicle, thymus, thyroid gland, trachea, urinary bladder, and uterus.
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Clinical findings included bilateral pupillary dilation in all dosed males and females and reddening of the eyes in 15 mg/kg males and 135, 400, and 1200 mg/kg males and females. Hyperactivity was visually observed in a few dosed males and females (males: 0 mg/kg, 0/10; 15 mg/kg, 0/10; 45 mg/kg, 1/10; 135 mg/kg, 1/10; 400 mg/kg, 0/10; 1200 mg/kg, 1/10; females: 0/10, 2/10, 5/10, 3/10, 1/10, 1/10). Hypoactivity was also visually observed in some other dosed males and females (males: 0/10, 0/10, 0/10, 0/10, 3/10, 3/10; females: 0/10, 0/10, 0/10, 1/10, 1/10, 5/10) and increased with increasing dose.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- One female receiving 45 mg/kg, two males and one female receiving 135 mg/kg, six males and one female receiving 400 mg/kg, and eight males and seven females receiving 1200 mg/kg died during the study (Table 1).
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- The final mean body weights and mean body weight gains of all dosed males and females were significantly lower than those of the control groups.The mortality and lower body weights of the dosed animals suggest that the dosed rats did not eat or drink as much as the controls and some dehydration would have occurred.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- The hematology data for rats in the 14 weeks study are listed in Table 2. Hematocrit, hemoglobin concentration, and/or erythrocyte count in male and female rats receiving 45 mg/kg or greater were slightly higher than those of the control groups. In general, these differences were most prominent in the 400 and 1200 mg/kg groups. Higher hematocrit, hemoglobin concentration, and erythrocyte count would be consistent with the hemoconcentration associated with dehydration (relative erythrocytosis). The mortality and lower body weights of the dosed animals suggest that the dosed rats did not eat or drink as much as the controls and some dehydration would have occurred. A minimal to mild mature neutrophilia, evidenced by higher segmented neutrophil numbers than those in the control group, occurred in all dosed male rats. Neutrophilia is often a result of an increased tissue demand for granulocytes due to inflammation. There was, however, no microscopic evidence of inflammation that could account for the neutrophilia. Thus, other mechanisms that alter granulopoiesis and/or rate of release from the bone marrow, redistribution of neutrophil life span could be considered. Other hematology differences were sporadic and were not treatment related.
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- The absolute and relative liver weights of 1200 mg/kg females were significantly greater than those of the control group. The absolute and relative thymus weights of 15, 45, 135, and 400 mg/kg males and females and 1200 mg/kg females were significantly lower than those of the control groups (Table 3).
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- no adverse effects
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- no adverse effects
- Histopathological findings: neoplastic:
- no effects observed
- Description (incidence and severity):
- no adverse effects
- Other effects:
- no effects observed
- Description (incidence and severity):
- Sperm morphology and vaginal cytology parameters in dosed rats were similar to those in the control groups.
- Details on results:
- The mortality and lower body weights of the dosed animals suggest that the dosed rats did not eat or drink as much as the controls and some dehydration would have occurred. Some males (0/10, 0/10, 0/10, 2/10, 3/10, 4/10) and females (0/10, 0/10, 1/10, 1/10, 0/10, 3/10) died from esophageal obstructions consisting of feed and bedding material in the posterior pharynx. Tracheal obstruction occurred concurrently with esophageal obstruction as a result of food build-up in the oropharyngeal region. This condition is considered to be secondary to the inhibitory effects of scopolamine hydrobromide trihydrate on salivary gland secretions and on esophageal smooth muscle involved in swallowing. There were no other significant treatment-related gross or microscopic findings.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 45 other: mg/kg bw
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- mortality
- Remarks on result:
- other: dosage 5 days a week converted in 32.14 mg/kg bw/day
- Dose descriptor:
- NOAEL
- Effect level:
- 400 other: mg/kg bw
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- mortality
- Remarks on result:
- other: dosage 5 days a week
- Critical effects observed:
- not specified
- Conclusions:
- Under the test conditions a NOAEL of 45 mg/kg bw (male) and a NOAEL of 400 mg/kg bw (female) was determined.
Reference
Table 1: Survival and Body Weights of Rats in the 14-Week Gavage Study of Scopolamine Hydrobromide Trihydrate
Mean Body Weight°° (g) | |||||
Dose (mg/kg) | Survival° | Initial | Final | Change | Final Weight Relative to Controls (%) |
Male | |||||
0 | 10/10 | 116 +-3 | 341 +-6 | 255 +-5 | |
15 | 10/10 | 116 +-3 | 312 +-7** | 197 +-6** | 92 |
45 | 10/10 | 115 +-3 | 302 +-4** | 188 +-5** | 89 |
135 | 8/10°°° | 114 +-3 | 300*-7** | 186 +-5** | 88 |
400 | 4/10°°°° | 115 +-2 | 304 +-3** | 188 +-7** | 89 |
1,200 | 2/10 °°°°° | 116 +-2 | 277 +-37** | 163 +-30** | 81 |
Female | |||||
0 | 10/10 | 96 +-1 | 203 +-2 | 107 +-2 | |
15 | 10/10 | 97 +-1 | 193 +-2** | 96 +-2** | 95 |
45 | 9/10°°°°°° | 98 +-2 | 196 +-2* | 97 +-1** | 97 |
135 | 9/10°°°°°°° | 95 +-1 | 190 +-2** | 96 +-3** | 94 |
400 | 9/10°°°°°° | 96 +-1 | 189 +-2** | 93 +-3** | 93 |
1200 | 3/10°°°°°°°° | 95 +-1 | 192 +-6** | 95 +-5** | 94 |
* Significantly different(P<=0.05) from the control group by Williams’ or Dunnett’s test
** P<=0.01
°Number of animals survivinglnumber initially in group. Subsequent calculations are based on animals surviving to the end of the study
°°Weights and weight changes are given as mean f standard error
°°°Week of death: 7, 14
°°°°Week of death: 1, 2,7, 7,13, 13
°°°°°Week of death: 1, 1, 1, 3, 4, 5, 9, 14
°°°°°°Week of death: 4
°°°°°°°Week of death: 8
°°°°°°°°Week of death: 1, 2,5, 6, 7, 7
Table 2: Hematology Data for Rats in the 14-WeekGavage Study of Scopolamine Hydrobromide Trihydrate°
Vehicle Control | 15 mg/kg | 45 mg/kg | 135 mg/kg | 400 rng/kg | 1,200 mg/kg | |
Male | ||||||
n | 10 | 9 | 10 | 8 | 4 | 1°° |
Hematocrit (%) | 46.8+-0.5 | 46.2+-0.4 | 48.0+-0.3* | 48.1+-0.3* | 49.0+-0.4** | 48.9 |
Hemoglobin (g/dL) | 15.2+-0.2 | 15.3+-0.2 | 15.7+-0.1 | 15.9 f 0.1* | 16.2+-0.1** | 16.4 |
Erythroctes (10^6/µL) | 9.39+-0.10 | 9.38+-0.10 | 9.63+-0.08 | 9.61 f 0.05 | 9.72+-0.11 | 9.58 |
Reticulocytes (10^6/µL) | 0.50+-0.03 | 0.47+-0.02 | 0.52+-0.03 | 0.42 f 0.03 | 0.40+-0.04 | 0.46 |
Nucleated erythrocytes (10^3/µL) | 0.03+-0.01 | 0.04+-0.01 | 0.01+-0.01 | 0.02+-0.01 | 0.02+-0.02 | 0.08 |
Mean cell volume (fL) | 49.9+-0.4 | 49.1+-0.1 | 50.0+-0.2 | 50.0+-0.3 | 50.5+-0.3 | 51.0 |
Mean cell hemoglobin (pg) | 16.2+-0.3 | 16.3+-0.1 | 16.3+-0.1 | 16.6+-0.1 | 16.7+-0.1 | 17 .1 |
Mean cell hemoglobin concentration (g/dL) | 32.6+-0.5 | 33.2+-0.1 | 32.8+-0.2 | 33.1+-0.2 | 33.1+-0.1 | 33.5 |
Platelets ( 10^3/µL) | 633.4+-20.8 | 638.8+10.6 | 655.8+-28.2°°° | 620.6+-20.6 | 621.5+-21.3 | 601.0 |
Leukocytes (10^3/µL) | 7.35+-0.44 | 6.96+-0.31 | 8.01+-0.36 | 7.59+-0.56 | 6.73+-0.57 | 8.40 |
Segmented neutrophils (10^3/µL) | 1.14+-0.13 | 1.89+-0.28* | 2.07+-0.17** | 1.82+-0.20** | 1.90+-0.12* | 2.69 |
Lymphocytes (10^3/µL) | 5.65+-0.35 | 4.68+-0.34 | 5.67+-0.41 | 5.37+-0.37 | 4.65+-0.45 | 5.38 |
Atypical lymphocytes (10^3/µL) | 0.12+-0.03 | 0.08+-0.03 | 0.04+-0.02 | 0.08+-0.05 | 0.00+-0.00 | 0.00 |
Monocytes (10^3/µL) | 0.35+-0.09 | 0.22+-0.06 | 0.17+-0.05 | 0.20+-0.04 | 0.07+-0.04* | 0.34 |
Eosinophils (10^3/µL) | 0.08+-0.03 | 0.09+-0.03 | 0.06+-0.01 | 0.11+-0.04 | 0.08+-0.02 | 0.00 |
Vehicle Control | 15 mg/kg | 45 mg/kg | 135 mg/kg | 400 rng/kg | 1,200 mg/kg | |
Female | ||||||
n | 9 | 10 | 9 | 9 | 8 | 3 |
Hematocrit (%) | 46.9+-0.4 | 47.4+-0.6 | 48.1+-0.4 | 47.6+-0.4 | 49.0+-0.4** | 49.1+-0.9* |
Hemoglobin (g/dL) | 15.6+-0.1 | 15.5+-0.2 | 15.9+-0.1 | 15.7+-0.2 | 16.2+-0.1** | 16.4+-0.3* |
Erythroctes (10^6/µL) | 8.82+-0.07 | 8.88+-0.11 | 9.09+-0.07* | 8.98+-0.10 | 9.17+-0.08* | 9.26+-0.17* |
Reticulocytes (10^6/µL) | 0.41+-0.02 | 0.38+-0.02 | 0.42+-0.03 | 0.43+-0.03 | 0.43+-0.03 | 0.42+-0.05 |
Nucleated erythrocytes (10^3/µL) | 0.02+-0.01 | 0.05+-0.01 | 0.03+-0.02 | 0.05+-0.02 | 0.05+-0.02 | 0.07+-0.07 |
Mean cell volume (fL) | 53.1+-0.3 | 53.2+-0.2 | 52.7+-0.2 | 53.1+-0.2 | 53.5+-0.3 | 53.0+-0.0 |
Mean cell hemoglobin (pg) | 17.7+-0.1 | 17.4+-0.1 | 17.5+-0.1 | 17.5+-0.1 | 17.7+-0.1 | 17.7+-0.1 |
Mean cell hemoglobin concentration (g/dL) | 33.3+-0.2 | 32.6+-0.1* | 33.1+-0.1 | 33.0+-0.2 | 33.1+-0.1 | 33.5+-0.2 |
Platelets ( 10^3/µL) | 759.6+-39.6 | 764.3+-31.7 | 758.4+-27.5 | 807.4+-29.8 | 810.1+-44.3 | 698.7+-14.6 |
Leukocytes (10^3/µL) | 6.37+-0.33 | 6.23+-0.40 | 6.21+-0.43 | 8.57+-0.38* | 7.39+-0.59 | 5.97+-0.91 |
Segmented neutrophils (10^3/µL) | 1.45+-0.11 | 1.30+-0.16 | 1.45+-0.12 | 2.16+-0.29 | 1.73+-0.17 | 1.68+-0.57 |
Lymphocytes (10^3/µL) | 4.63+-0.36 | 4.68+-0.25 | 4.48+-0.42 | 6.15+-0.25* | 5.35+-0.48 | 4.10+-0.38 |
Atypical lymphocytes (10^3/µL) | 0.09+-0.04 | 0.03+-0.03 | 0.02+-0.01 | 0.04+-0.04 | 0.04+-0.03 | 0.04+-0.02 |
Monocytes (10^3/µL) | 0.14+-0.05 | 0.15+-0.04 | 0.18+-0.06 | 0.15+-0.07 | 0.20+-0.08 | 0.08+-0.03 |
Eosinophils (10^3/µL) | 0.06+-0.01 | 0.07+-0.02 | 0.07+-0.02 | 0.07+-0.03 | 0.04+-0.01 | 0.07+-0.04 |
* Significantly different (P<=0.05) from the control group by Dunn’s or Shirley’s test
** P<=0.01
° Mean f standarderror.Statisticaltests wereperformedonunroundeddata.
°°n=l; no standard error calculated
°°n=9
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 32.14 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Quality of whole database:
- According to Annex VI of regulation No 1272/2008 (CLP regulation) the test item is classified as Acute Toxic Category 1 (H310) referred to dermal toxicity to skin (has to be completed)
Additional information
From the National Toxicology Program (NTP) a technical report on the toxicology and carcinogenesis studies of the read across substance scopolamine hydrobromide trihydrate in rats and mice (gavage studies) (NTP TR 445) is available. This report includes i.a. data for repeated dose toxicity tests (subacute and subchronic) with mice and rats. All tests were conducted in accordance with good scientific principles.
For the subacute (16 -days) repeated dose toxicity study in rats (F344/N) and mice (B6C3F1) a NOAEL of >1200 mg/kg bw (female/male) was determined for rats and a NOAEL of 900 mg/kg bw (female/male) was determined for mice.
For the subchronic 14 -weeks repeated dose toxicity study in rats (F344/N) and mice (B6C3F1) a NOAEL of 45 mg/kg bw (male) and a NOAEL of 400 mg/kg bw (female) was determined for rats and a NOAEL of 400 mg/kg bw (male/female) in mice. Based on this data the lowest NOAEL of 45 mg/kg bw determined in the 14 -weeks study with rats was selected as key value. The exposure for five days per week under test conditions was extrapolated to seven days per week resulting in the NOAEL value of 32.14 mg/kg bw/day. For DNEL calculation the most sensitive NOAEL value was used, which was determined in the chronic carcinogenicity study (refer to section 5.8.).
All NOAEL values determined in this studies are based on survival.
Justification for classification or non-classification
Based on the available data, the substance will not be classified.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.